SLC5A1 and type 2 diabetes mellitus: Although SGLT1 is thought to be an important cardiac glucose transporter in type 2 diabetic patients (Szablewski, 2017), a recent study demonstrated that phlorizin, a dual SGLT1/2 inhibitor, can reduce cardiomyocyte glucose uptake independent of SGLT1, suggesting that SGLT1/2 inhibitor might inhibit other glucose transporters (Ferte et al., 2021).